Hims & Hers Health, Inc. (NYSE:HIMS) Receives $24.80 Consensus Price Target from Analysts

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been assigned an average rating of “Hold” from the seventeen ratings firms that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $25.13.

Several equities research analysts have recently commented on HIMS shares. Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their target price for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. Needham & Company LLC upped their target price on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 6th. Morgan Stanley started coverage on shares of Hims & Hers Health in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $33.56, for a total transaction of $68,932.24. Following the sale, the insider now directly owns 184,947 shares in the company, valued at approximately $6,206,821.32. This trade represents a 1.10 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the completion of the transaction, the chief executive officer now owns 67,015 shares of the company’s stock, valued at $1,399,273.20. This trade represents a 73.81 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,080,208 shares of company stock worth $29,106,823. Corporate insiders own 17.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its holdings in shares of Hims & Hers Health by 2,173.7% in the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock valued at $54,000 after purchasing an additional 2,152 shares during the last quarter. Quest Partners LLC grew its position in Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares in the last quarter. CWM LLC increased its stake in Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares during the last quarter. Quarry LP lifted its position in Hims & Hers Health by 91.0% during the 3rd quarter. Quarry LP now owns 6,113 shares of the company’s stock worth $113,000 after buying an additional 2,913 shares in the last quarter. Finally, Amalgamated Bank lifted its position in Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after buying an additional 2,354 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Up 1.1 %

Shares of NYSE HIMS opened at $26.19 on Friday. Hims & Hers Health has a 12-month low of $8.14 and a 12-month high of $35.02. The firm’s 50-day simple moving average is $27.42 and its 200 day simple moving average is $21.72. The company has a market cap of $5.72 billion, a price-to-earnings ratio of 59.52 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Hims & Hers Health’s quarterly revenue was up 77.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.04) earnings per share. On average, equities analysts expect that Hims & Hers Health will post 0.29 earnings per share for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.